Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics S.A.    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

GenSight Biologics S A : Appoints Elsy Boglioli to its Board of Directors

10/15/2020 | 08:23am EST

Paris - GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the appointment of Elsy Boglioli to its Board of Directors, replacing Bpifrance Participations.

Mrs. Boglioli is joining as an independent Director.

'I am particularly excited to be joining the GenSight team as they have just filed for approval of LUMEVOQ, their lead product for the treatment of LHON,' commented Elsy Boglioli. 'I look forward to working with the management team and the Board in order to make this product available to patients in need, as soon as possible, and in multiple geographies - hence fueling company growth and transformation.'

Elsy is the founder and Chief Executive Officer of Bio-Up, a healthcare advisory firm supporting companies in strong scale up or transformation phases, mainly in the field of cell and gene therapy. She has far-reaching expertise and a broad network within the pharma and medtech industries.

Before she created Bio-Up, Elsy was Executive Vice President, Chief Operating Officer at Cellectis, a French biotechnology company focused on gene editing and its applications in oncology. At Cellectis she led various strategic and operational functions: strategy, business development, clinical trials program management, as well as manufacturing, with the objective of building in-house capacity. Prior to joining Cellectis, Elsy worked at the Boston Consulting Group (BCG) for 12 years. She served as Partner and Managing Director in the Paris Office, was the leader of BCG's biotech-focused business in Europe. She worked closely with biotech and pharma companies on topics such as specialty product launch optimization, partnering and M&A.

Elsy graduated from the Ecole Polytechnique in Paris, France and holds a master's degree in economy and management from the Pompeu Fabra University in Barcelona, Spain. She also completed a College degree in Immuno-oncology at Institut Gustave Roussy in Paris, France.

'As we are transforming from an R&D company to a commercial organization, Elsy's extensive experience in both the pharma industry and corporate strategy will be a fantastic contribution to GenSight,' said Bernard Gilly, Chief Executive Officer of GenSight Biologics. 'I take the opportunity to thank Bpifrance Participations for their support on the journey from the IPO to the European regulatory filing of LUMEVOQ.'

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, LUMEVOQ (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

Contact:

Thomas Gidoin

Tel: +33 (0)1 76 21 72 20

Email: tgidoin@gensight-biologics.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CELLECTIS 0.54% 18.68 End-of-day quote.18.49%
GENSIGHT BIOLOGICS S.A. 7.87% 6.03 End-of-day quote.124.95%
All news about GENSIGHT BIOLOGICS S.A.
11/04GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ Marketing Authorisation A..
AQ
11/03GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ® Marketing Authorisation ..
PU
11/03GENSIGHT BIOLOGICS : Reports Validation of LUMEVOQ® Marketing Authorisation Appl..
BU
10/23GENSIGHT BIOLOGICS S A : successfully raises EUR25 million in an oversubscribed ..
AQ
10/22GENSIGHT BIOLOGICS S A : Securities Note
PU
10/22GENSIGHT BIOLOGICS S A : Amendment to the 2019 Universal Registration Document
PU
10/22GENSIGHT BIOLOGICS S A : launches a capital increase of approximately EUR25 mill..
AQ
10/22GENSIGHT BIOLOGICS S A : successfully raises €25 million in an oversubscribed pr..
PU
10/22GENSIGHT BIOLOGICS S A : Successfully Raises €25 Million in an Oversubscribed Pr..
BU
10/21GENSIGHT BIOLOGICS S A : launches a capital increase of approximately €25 millio..
PU
More news
Financials
Sales 2020 12,5 M 14,8 M 14,8 M
Net income 2020 -16,7 M -19,8 M -19,8 M
Net cash 2020 16,7 M 19,9 M 19,9 M
P/E ratio 2020 -9,42x
Yield 2020 -
Capitalization 221 M 263 M 263 M
EV / Sales 2020 16,4x
EV / Sales 2021 14,5x
Nbr of Employees 25
Free-Float 95,4%
Chart GENSIGHT BIOLOGICS S.A.
Duration : Period :
GenSight Biologics S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSIGHT BIOLOGICS S.A.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 10,23 €
Last Close Price 5,59 €
Spread / Highest target 150%
Spread / Average Target 83,1%
Spread / Lowest Target 19,9%
EPS Revisions
Managers
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Chairman
Thomas Gidoin Chief Financial Officer
Magali Taiel Chief Medical Officer
José-Alain Sahel Director
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS S.A.124.95%263
GILEAD SCIENCES, INC.-7.28%75 525
VERTEX PHARMACEUTICALS-1.12%56 298
REGENERON PHARMACEUTICALS34.79%53 416
WUXI APPTEC CO., LTD.59.64%38 761
BIONTECH SE200.68%24 529